MedTrace Logo

TRU-IMMUNO: Optimizing Liver Immunosuppression

NCT05335551 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2022-05-02

No results posted yet for this study

Summary

This is a prospective, multi-center, randomized study. The primary objective is to evaluate the feasibility and utility of TruGraf/TRAC Liver testing used in addition to standard of care measures of liver dysfunction to guide immunosuppression management.

Conditions

  • Liver Transplant Rejection

Interventions

DIAGNOSTIC_TEST

Patients monitored with TruGraf and TRAC Liver testing

This is an observational study there are no protocol mandated interventions. TruGraf and TRAC Liver results will be utilized in conjunction with standard of care assessments to determine patient management in the study arm.

Sponsors & Collaborators

  • Transplant Genomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Patty West-Thielke, PharmD · Transplant Genomics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2023-05-31
Completion
2023-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05335551 on ClinicalTrials.gov